Effectiveness of Nationwide COPD Pay-for-Performance Program on COPD Exacerbations in Taiwan

References

• Moraga P. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1151–1210. doi:10.1016/S0140-6736(17)32152-9.
   PubMed Web of Science ®Google Scholar
• Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53:1900164. doi:10.1183/13993003.00164-2019
   PubMed Web of Science ®Google Scholar
• Cheng SL, Chan MC, Wang CC, et al. COPD in Taiwan: a National Epidemiology Survey. Int J Chron Obstruct Pulmon Dis. 2015;10:2459–2467. doi:10.2147/COPD.S89672
   PubMed Web of Science ®Google Scholar
• Hsiao AJ, Chen LH, Lu TH. Ten leading causes of death in Taiwan: a comparison of two grouping lists. J Formos Med Assoc. 2015;114(8):679–680. doi:10.1016/j.jfma.2013.12.003
   PubMed Web of Science ®Google Scholar
• Wei YF, Tsai YH, Wang CC, et al. Impact of overweight and obesity on acute exacerbations of COPD - subgroup analysis of the Taiwan Obstructive Lung Disease cohort. Int J Chron Obstruct Pulmon Dis. 2017;12:2723–2729. doi:10.2147/COPD.S138571
   PubMed Web of Science ®Google Scholar
• World Health Organisation (WHO). Chronic respiratory diseases. Burden of COPD; 2019. Available from: www.who.int/respiratory/copd/burden/en/. Accessed July 19, 2019.
   Google Scholar
• Singh D, Agusti A, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164. doi:10.1183/13993003.00164-2019
   PubMed Web of Science ®Google Scholar
• Ko FW, Chan KP, Hui DS, et al. Acute exacerbation of COPD. Respirology. 2016;21:1152–1165. doi:10.1111/resp.12780
   PubMed Web of Science ®Google Scholar
• Chiang CH. Cost analysis of chronic obstructive pulmonary disease in a tertiary care setting in Taiwan. Respirology. 2008;13(5):689–694. doi:10.1111/j.1440-1843.2008.01308.x
   PubMed Web of Science ®Google Scholar
• Blasi F, Cesana G, Conti S, et al. The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patients. PLoS One. 2014;9(6):e101228. doi:10.1371/journal.pone.0101228
   PubMed Web of Science ®Google Scholar
• Ho TW, Tsai YJ, Ruan SY, et al. In-hospital and one-year mortality and their predictors in patients hospitalized for first-ever chronic obstructive pulmonary disease exacerbations: a nationwide population-based study. PLoS One. 2014;9(12):e114866. doi:10.1371/journal.pone.0114866
   PubMed Web of Science ®Google Scholar
• Lim S, Lam DC, Muttalif AR, et al. Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey. Asia Pac Fam Med. 2015;14(1):4. doi:10.1371/journal.pone.0114866
   PubMedGoogle Scholar
• Gagliardi AR, Brouwers MC, Palda VA, et al. How can we improve guideline use? A conceptual framework of implementability. Implement Sci. 2011;6:26. doi:10.1186/1748-5908-6-26.3
   PubMed Web of Science ®Google Scholar
• Kastner M, Bhattacharyya O, Hayden L, et al. Guideline uptake is influenced by six implementability domains for creating and communicating guidelines: a realist review. J Clin Epidemiol. 2015;68(5):498–509. doi:10.1016/j.jclinepi.2014.12.013
   PubMed Web of Science ®Google Scholar
• Sehl J, O’Doherty J, O’Connor R, et al. Adherence to COPD management guidelines in general practice? A review of the literature. Ir J Med Sci. 2018;187(2):403–407. doi:10.1007/s11845-017-1651-7
   PubMed Web of Science ®Google Scholar
• Overington JD, Huang YC, Abramson MJ, et al. Implementing clinical guidelines for chronic obstructive pulmonary disease: barriers and solutions. J Thorac Dis. 2014;6(11):1586–1596. doi:10.3978/j.issn.2072-1439.2014.11.25
   PubMed Web of Science ®Google Scholar
• Hsieh MJ, Huang SY, Yang TM, et al. The impact of 2011 and 2017 Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guidelines on allocation and pharmacological management of patients with COPD in Taiwan: Taiwan Obstructive Lung Disease (TOLD) study. Int J Chron Obstruct Pulmon Dis. 2018;13:2949–2959. doi:10.2147/COPD.S176065
   PubMed Web of Science ®Google Scholar
• López-Campos JL, Hartl S, Pozo-Rodriguez F, et al. Antibiotic prescription for COPD exacerbations admitted to hospital: European COPD audit. PLoS One. 2015;10(4):e0124374. doi:10.1371/journal.pone.0124374
   PubMed Web of Science ®Google Scholar
• Tang CY, Taylor NF, McDonald CF, et al. Level of adherence to the GOLD strategy document for management of patients admitted to hospital with an acute exacerbation of COPD. Respirology. 2014;19(8):1191–1197. doi:10.1111/resp.12361
   PubMed Web of Science ®Google Scholar
• Vlaev I, King D, Darzi A, et al. Changing health behaviors using financial incentives: a review from behavioral economics. BMC Public Health. 2019;19(1):1059. doi:10.1186/s12889-019-7407-8
   PubMed Web of Science ®Google Scholar
• Cutler DM, Ghosh K. The potential for cost savings through bundled episode payments. N Engl J Med. 2012;366(12):1075–1077. doi:10.1056/NEJMp1113361
   PubMed Web of Science ®Google Scholar
• Kyeremanteng K, Robidoux R, D’Egidio G, et al. An analysis of pay-for-performance schemes and their potential impacts on health systems and outcomes for patients. Crit Care Res Pract. 2019;2019:8943972. doi:10.1155/2019/8943972
   PubMed Web of Science ®Google Scholar
• Lee IT, Hsu CC, Sheu WH, et al. Pay-for-performance for shared care of diabetes in Taiwan. J Formos Med Assoc. 2019;118(Suppl 2):S122–S129. doi:10.1016/j.jfma.2019.08.011
   PubMed Web of Science ®Google Scholar
• Chen TT, Yang JJ, Hsueh YA, et al. The effects of a schizophrenia pay-for-performance program on patient outcomes in Taiwan. Health Serv Res. 2019;54(5):1119–1125. doi:10.1111/1475-6773.13174
   PubMed Web of Science ®Google Scholar
• Chen HJ, Huang N, Chen LS, et al. Does pay-for-performance program increase providers adherence to guidelines for managing Hepatitis B and Hepatitis C virus infection in Taiwan? PLoS One. 2016;11(8):e0161002. doi:10.1371/journal.pone.0161002
   PubMed Web of Science ®Google Scholar
• Lin TY, Chen CY, Huang YT, et al. The effectiveness of a pay for performance program on diabetes care in Taiwan: a nationwide population-based longitudinal study. Health Policy (New York). 2016;120(11):1313–1321. doi:10.1016/j.healthpol.2016.09.014
   Web of Science ®Google Scholar
• Wang CJ, Cheng SH, Wu JY, et al. Association of a bundled-payment program with cost and outcomes in full-cycle breast cancer care. JAMA Oncol. 2017;3(3):327–334. doi:10.1001/jamaoncol.2016.4549
   PubMed Web of Science ®Google Scholar
• Huang YC, Lee MC, Chou YJ, et al. Disease-specific pay-for-performance programs: do the P4P effects differ between diabetic patients with and without multiple chronic conditions? Med Care. 2016;54(11):977–983. doi:10.1097/MLR.0000000000000598
   PubMed Web of Science ®Google Scholar
• Hsieh HM, Lin MY, Chiu YW, et al. Economic evaluation of a pre-ESRD pay-for-performance programme in advanced chronic kidney disease patients. Nephrol Dial Transplant. 2017;32(7):1184–1194. doi:10.1093/ndt/gfw372
   PubMed Web of Science ®Google Scholar
• Cheng SH, Lee TT, Chen CC. A longitudinal examination of a pay-for-performance program for diabetes care: evidence from a natural experiment. Med Care. 2012;50(2):109–116. doi:10.1097/MLR.0b013e31822d5d36
   PubMed Web of Science ®Google Scholar
• Pham HH, Schrag D, O’Malley AS, et al. Care patterns in Medicare and their implications for pay for performance. N Engl J Med. 2007;356(11):1130–1139. PMID: 17360991. doi:10.1056/NEJMsa063979
   PubMed Web of Science ®Google Scholar
• Chen TT, Chung KP, Lin IC, et al. The unintended consequence of diabetes mellitus pay-for-performance (P4P) program in Taiwan: are patients with more comorbidities or more severe conditions likely to be excluded from the P4P program? Health Serv Res. 2011;46(1 Pt 1):47–60. doi:10.1111/j.1475-6773.2010.01182.x
   PubMed Web of Science ®Google Scholar
• Fitzmaurice GM, Laird NM, Ware JH. Applied Longitudinal Analysis. Hoboken, NJ: Wiley; 2004.
   Google Scholar
• Grover A, Joshi A. An overview of chronic disease models: a systematic literature review. Glob J Health Sci. 2014;7(2):210–227. doi:10.5539/gjhs.v7n2p210
   PubMedGoogle Scholar
• Chen TT, Oldenburg B, Hsueh YS. Chronic care model in the diabetes pay-for-performance program in Taiwan: benefits, challenges and future directions. World J Diabetes. 2021;12(5):578–589. doi:10.4239/wjd.v12.i5.578
   PubMed Web of Science ®Google Scholar
• Adams SG, Smith PK, Allan PF, et al. Systematic review of the chronic care model in chronic obstructive pulmonary disease prevention and management. Arch Intern Med. 2007;167(6):551–561. doi:10.1001/archinte.167.6.551
   PubMed Web of Science ®Google Scholar
• Albitar HAH, Iyer VN. Adherence to global initiative for chronic obstructive lung disease guidelines in the real world: current understanding, barriers, and solutions. Curr Opin Pulm Med. 2020;26(2):149–154. doi:10.1097/MCP.0000000000000655
   PubMed Web of Science ®Google Scholar
• Hsieh MJ, Huang SY, Yang TM, et al. The impact of 2011 and 2017 Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) guidelines on allocation and pharmacological management of patients with COPD in Taiwan: Taiwan Obstructive Lung Disease (TOLD) study. Int J Chron Obstruct Pulmon Dis. 2018;13:2949–2959. doi:10.2147/COPD.S176065
   PubMed Web of Science ®Google Scholar
• Palli SR, Zhou S, Shaikh A, et al. Effect of compliance with GOLD treatment recommendations on COPD health care resource utilization, cost, and exacerbations among patients with COPD on maintenance therapy. J Manag Care Spec Pharm. 2021;27(5):625–637. doi:10.18553/jmcp.2021.20390
   PubMed Web of Science ®Google Scholar
• Mannino DM, Yu TC, Zhou H, et al. Effects of GOLD-adherent prescribing on COPD symptom burden, exacerbations, and health care utilization in a real-world setting. Chronic Obstr Pulm Dis. 2015;2(3):223–235. doi:10.15326/jcopdf.2.3.2014.0151
   PubMedGoogle Scholar
• Sehl J, O’Doherty J, O’Connor R, et al. Adherence to COPD management guidelines in general practice? A review of the literature. Ir J Med Sci. 2018;187(2):403–407. doi:10.1007/s11845-017-1651-7
   PubMed Web of Science ®Google Scholar
• Tabyshova A, Hurst JR, Soriano JB, et al. Gaps in COPD guidelines of low- and middle-income countries: a systematic scoping review. Chest. 2021;159(2):575–584. doi:10.1016/j.chest.2020.09.260
   PubMed Web of Science ®Google Scholar
• de Bruin SR, Baan CA, Struijs JN. Pay-for-performance in disease management: a systematic review of the literature. BMC Health Serv Res. 2011;14(11):272. doi:10.1186/1472-6963-11-272
   Web of Science ®Google Scholar
• Alshamsan R, Millett C, Majeed A, Khunti K. Has pay for performance improved the management of diabetes in the United Kingdom? Prim Care Diabetes. 2010;4(2):73–78. doi:10.1186/1472-6963-11-272
   PubMed Web of Science ®Google Scholar
• Lin MT, Hsu CN, Lee CT, et al. Effect of a pay-for-performance program on renal outcomes among patients with early-stage chronic kidney disease in Taiwan. Int J Health Policy Manag. 2021;13. doi:10.34172/ijhpm.2021.27
   Web of Science ®Google Scholar
• Petersen LA. Pay for performance: what we measure matters. Virtual Mentor. 2013;15(7):570–575. doi:10.1001/virtualmentor.2013.15.7.ecas2-1307
   PubMedGoogle Scholar
• Lanning E, Longstaff J, Jones T, et al. Modern Innovative Solutions in Improving Outcomes in Chronic Obstructive Pulmonary Disease (MISSION COPD): mixed methods evaluation of a novel integrated care clinic. Interact J Med Res. 2019;8(4):e9637. doi:10.2196/ijmr.9637
   PubMed Web of Science ®Google Scholar
• Peckens S, Adelman MM, Ashcraft AM, et al. Improving Chronic Obstructive Pulmonary Disease (COPD) symptoms using a team-based approach. J Am Board Fam Med. 2020;33(6):978–985. doi:10.3122/jabfm.2020.06.200176
   PubMed Web of Science ®Google Scholar
• Ho TW, Tsai YJ, Huang CT, Lien AS, Lai F. Impact of tobacco-related chronic obstructive pulmonary disease on developmental trajectories of comorbidities in the Taiwan population. Sci Rep. 2020;10(1):21025. doi:10.1038/s41598-020-78325-y
   PubMed Web of Science ®Google Scholar
• Westerik JA, Metting EI, van Boven JF, et al. Associations between chronic comorbidity and exacerbation risk in primary care patients with COPD. Respir Res. 2017;18(1):31. doi:10.1186/s12931-017-0512-2
   PubMed Web of Science ®Google Scholar
• Schwab P, Dhamane AD, Hopson SD, et al. Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly medicare population. Int J Chron Obstruct Pulmon Dis. 2017;12:735–744. doi:10.2147/COPD.S112256
   PubMed Web of Science ®Google Scholar
• Hogea SP, Tudorache E, Fildan AP, et al. Risk factors of chronic obstructive pulmonary disease exacerbations. Clin Respir J. 2020;14(3):183–197. doi:10.1016/S0140-6736(11)60968-9
   PubMed Web of Science ®Google Scholar
• Huang YC, Lee MC, Chou YJ, Huang N. Disease-specific pay-for-performance programs: do the P4P effects differ between diabetic patients with and without multiple chronic conditions? Med Care. 2016;54(11):977–983. doi:10.1097/MLR.0000000000000598
   PubMed Web of Science ®Google Scholar
• Chung SM, Lee SY. Evaluation of appropriate management of chronic obstructive pulmonary disease in Korea: based on Health Insurance Review and Assessment Service (HIRA) claims. Tuberc Respir Dis (Seoul). 2017;80(3):241–246. doi:10.4046/trd.2017.80.3.241
   PubMedGoogle Scholar
• Hsieh HM, Gu SM, Shin SJ, et al. Cost-effectiveness of a diabetes pay-for-performance program in diabetes patients with multiple chronic conditions. PLoS One. 2015;10(7):e0133163. doi:10.1371/journal.pone.0133163
   PubMed Web of Science ®Google Scholar
• Rhee CK, Yoshisue H, Lad R. Fixed-dose combinations of long-acting bronchodilators for the management of COPD: global and asian perspectives. Adv Ther. 2019;36(3):495–519. doi:10.1007/s12325-019-0893-3
   PubMed Web of Science ®Google Scholar
• Mammen MJ, Pai V, Aaron SD, et al. Dual LABA/LAMA therapy versus LABA or LAMA monotherapy for chronic obstructive pulmonary disease. A systematic review and meta-analysis in support of the American Thoracic Society clinical practice guideline. Ann Am Thorac Soc. 2020;17(9):1133–1143. doi:10.1513/AnnalsATS.201912-915OC
   PubMed Web of Science ®Google Scholar
• Tsai YH, Yang TM, Lin CM, et al. Trends in health care resource utilization and pharmacological management of COPD in Taiwan from 2004 to 2010. Int J Chron Obstruct Pulmon Dis. 2017;12:2787–2793. doi:10.2147/COPD.S147968
   PubMed Web of Science ®Google Scholar
• Achelrod D, Welte T, Schreyögg J, et al. Costs and outcomes of the German disease management programme (DMP) for chronic obstructive pulmonary disease (COPD)-a large population-based cohort study. Health Policy (New York). 2016;120(9):1029–1039. doi:10.1016/j.healthpol.2016.08.002
   Web of Science ®Google Scholar
• Lee TT, Cheng SH, Chen CC, et al. A pay-for-performance program for diabetes care in Taiwan: a preliminary assessment. Am J Manag Care. 2010;16(1):65–69.
   PubMed Web of Science ®Google Scholar